Earlier this year, I wrote about the growing role of bad faith in trade mark disputes and how technology is changing the landscape. It is now much easier to identify an overseas brand, check whether it is protected in Australia…
A recent decision of the United States Court of Appeals for the Federal Circuit has highlighted the risks of claiming broad pharmaceutical dosage regimens without providing enough practical guidance in the patent specification. In Wyeth LLC v AstraZeneca Pharmaceuticals LP,…
Australian companies engaged in research and development increasingly collaborate with overseas inventors as part of global R&D programs. China and India, in particular, are key partners for Australian businesses developing advanced technologies in sectors such as mining, energy, medical devices…
If you own a US trade mark registration, it is important to be aware that you’re required to periodically file proof that you’re still using the mark in the US. If you don’t, your registration will be cancelled. There is…
The Federal Court’s decision in Mobile Skips (Australia) Pty Ltd v Registrar of Trade Marks FCA 744 is a timely reminder that a registered logo mark does not necessarily give the owner exclusive rights in the words appearing within that…
Patent term extensions (PTEs) in Australia sit at the centre of a long-running tension between innovation policy and statutory interpretation. Introduced to compensate pharmaceutical patentees for regulatory delay, the regime has increasingly been asked to do more than it was…